SCHEMBL21945751

SCHEMBL21945751

C[C@]1(O)C[C@@H](NC(=O)OCc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
GAA P10253 1/20 0.60
TSHR P16473 3/20 0.58
EPHX1 P07099 1/20 0.54
CTSL P07711 1/20 0.52
CTSB P07858 1/20 0.52
CTSK P43235 1/20 0.52
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
ACHE P22303 2/20 0.50
ROCK2 O75116 1/20 0.49
ENPP2 Q13822 1/20 0.49
ATXN2 Q99700 1/20 0.49
CYP3A4 P08684 2/20 0.49
CASP1 P29466 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CPB1 P15086 1/20 0.49
LMNA P02545 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21945750 1.00 ALDH1A1 (0.60) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL21946019 1.00 ALDH1A1 (0.60) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL6758979 0.90 ALDH1A1 (0.62) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL21677283 0.87 EPHX1 (0.57) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL21677282 0.87 EPHX1 (0.57) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL14646988 0.86 ALDH1A1 (0.65) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL31641122 0.86 ALDH1A1 (0.58) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL28567212 0.86 EZH2 (0.60) ALDH1A1GAATSHREPHX1ENPP2
SCHEMBL21945637 0.86 ALDH1A1 (0.58) ALDH1A1GAATSHREPHX1CTSL
SCHEMBL20064074 0.86 ALDH1A1 (0.65) ALDH1A1GAATSHREPHX1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089571-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2022-03-24 US disclosed
US-11149035-B2 Chemical compounds as H—PGDS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) 2021-10-19 US disclosed
WO-2020150113-A1 SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER INNATE TUMOR IMMUNITY, INC. (US) 2020-07-23 WO disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149035-B2 Chemical compounds as H—PGDS inhibitors HPGDS, PTGS1, PTGIS ALDH1A1 918/4885GAA 814/4885TSHR 4104/4885
US-20220089571-A1 NLRP3 MODULATORS NLRP3, NLRP1, PYCARD ALDH1A1 789/4885GAA 2767/4885TSHR 4777/4885
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors HPGDS, PTGS1, PTGIS ALDH1A1 889/4885GAA 785/4885TSHR 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.